Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes

[1] Jimi E(1999)Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function J Immunol 163 434-442

[2] Akiyama S(2002)Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis Ann Rheum Dis 61 1047-1054

[3] Tsurukai T(2008)Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis Clin Exp Rheumatol 26 240-246

[4] Okahashi N(2008)IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17 Rheumatology (Oxford) 47 1635-1640

[5] Kobayashi K(2008)Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption Arthritis Rheum 58 2397-2408

[6] Udagawa N(2005)Negative regulation of cytokine signaling and immune responses by SOCS proteins Arthritis Res Ther 7 100-110

[7] Nishihara T(2000)Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors Oncogene 19 2548-2556

[8] Takahashi N(2011)IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis Int Immunol 23 701-712

[9] Suda T(1999)STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone J Biol Chem 274 19301-19308

[10] Crotti TN(2001)Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis J Clin Invest 108 1781-1788

[1] Jimi E(1999)Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function J Immunol 163 434-442

[2] Akiyama S(2002)Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis Ann Rheum Dis 61 1047-1054

[3] Tsurukai T(2008)Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis Clin Exp Rheumatol 26 240-246

[4] Okahashi N(2008)IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17 Rheumatology (Oxford) 47 1635-1640

[5] Kobayashi K(2008)Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption Arthritis Rheum 58 2397-2408

[6] Udagawa N(2005)Negative regulation of cytokine signaling and immune responses by SOCS proteins Arthritis Res Ther 7 100-110

[7] Nishihara T(2000)Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors Oncogene 19 2548-2556

[8] Takahashi N(2011)IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis Int Immunol 23 701-712

[9] Suda T(1999)STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone J Biol Chem 274 19301-19308

[10] Crotti TN(2001)Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis J Clin Invest 108 1781-1788